Cellyan Biotechnology Co., Ltd (HKPD) Stock Price & Analysis
Cellyan Biotechnology Co., Ltd (HKPD) — MoonshotScore 37/100 (Weak band), calculated Oct 5, 2026. Price $0.1095 (-2.06%), as of the Oct 2, 2026 trading session; market cap $1.20M.
Educational signal · not a buy or sell recommendation · How to read this
Cellyan Biotechnology Co., Ltd · HKPD
Cellyan Biotechnology Co., Ltd (HKPD) is an investment holding entity specializing in international sourcing and distribution of over-the-counter (OTC) pharmaceuticals across Hong Kong and mainland China. The company also provides comprehensive e-commerce supply chain management and logistical support, serving a diverse clientele including e-commerce logistics partners, merchants, and pharmaceutical distributors.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Cellyan Biotechnology Co. (HKPD)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Cheap, but a strained balance sheet, stalling growth and average quality, and the price trend has turned against it. Business Quality: Average; Financial Safety: Strained; Valuation: Fair; Growth Durability: Shrinking; Momentum: Falling.
- quarterly revenue $6M (Q4 FY2026, quarter ended Mar 2026)
- Altman Z 3.53 · Piotroski F 4
- ROE -15.4% · ROA -8.8% · current ratio 3.86 · earnings yield -28.6% · free-cash-flow yield -65.1%
Holding back: soft growth, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 37 | Weak | |
| 37 | Weak | |
| 37 | Weak | |
| 37 | Weak | |
| 37 | Weak | |
| 37 | Weak |
The score was 37 in the stored Oct 4, 2026 snapshot and remains 37 in the current publication computed Oct 5, 2026 (0). This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.1095 | |
| Change on the day | -2.06% | |
| 52-week range | $0.096 – $1.72 | |
| Market capitalisation | $1.20M | |
| Shares traded on the day | 259.8K |
Price & events
Other perspectives
Council score for Cellyan Biotechnology Co. (HKPD): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the HKPD film — every key number, told as a short cinematic story
~2 min · open the film
What is Cellyan Biotechnology Co. (HKPD), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cellyan Biotechnology Co., Ltd (HKPD) is the company analyzed here. It employs 27 people and is led by Chenyu Liang. In Q4 FY2026 it reported revenue of $6M and net income of -$1M. The market values it at $1.20M.
What do the latest results show for Cellyan Biotechnology Co. (HKPD)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $6M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $6M | -$1M | -$0.04 (diluted) |
| Q2 FY2026 | $7M | $153,735 | $0.01 (diluted) |
| Q4 FY2025 | $9M | -$855,616 | -$0.08 (diluted) |
| Q2 FY2025 | $11M | $828,560 | $0.08 (diluted) |
What are the financial strengths and risks for Cellyan Biotechnology Co. (HKPD)?
Short answer
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is soft growth, weak price trend. The distress and quality screens read Altman Z 3.53 · Piotroski F 4. Trailing ratios: ROE -15.4% · ROA -8.8% · current ratio 3.86 · earnings yield -28.6% · free-cash-flow yield -65.1%.
How does Cellyan Biotechnology Co. compare with its peers?
Short answer
Cellyan Biotechnology Co.'s score ranks 7th of 9 in the bounded comparison shown, against 8 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $42.10 Oct 5, 2026 | $2.70B | 97 5-pillar Oct 5, 2026 | |
| $915.45 Oct 5, 2026 | $106B | 90 5-pillar Oct 5, 2026 | |
| $233.12 Oct 5, 2026 | $53.5B | 88 5-pillar Oct 5, 2026 | |
| $314.93 Oct 5, 2026 | $60.1B | 81 5-pillar Oct 5, 2026 | |
| $84.23 Oct 5, 2026 | $9.67B | 75 5-pillar Oct 5, 2026 | |
| $45.60 Oct 5, 2026 | $2.16B | 62 5-pillar Oct 5, 2026 | |
| Cellyan Biotechnology Co. (HKPD) — this page | $0.1095 | $1.20M | 37 |
| $0.89 Oct 5, 2026 | — | 33 5-pillar Oct 5, 2026 | |
| $0.46 Oct 5, 2026 | $38.7M | 28 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
What Investors Ask About Cellyan Biotechnology Co. (HKPD)
These answers are editorial: 1 of these 9 answers is drawn from the HKPD research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for HKPD?
HKPD carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is HKPD a good stock to buy?
Stock Expert AI does not rate HKPD buy, sell or hold. Cellyan Biotechnology Co., Ltd carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the HKPD stock price today?
The last price recorded on this page for Cellyan Biotechnology Co., Ltd (HKPD) is $0.1095, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is Cellyan Biotechnology Co., Ltd's core business model and market focus?
Cellyan Biotechnology Co., Ltd operates as an investment holding entity with a primary focus on the over-the-counter (OTC) pharmaceutical sector.
What are the key factors to evaluate for HKPD?
Cellyan Biotechnology Co., Ltd (HKPD) holds a MoonshotScore in the low range. The core business involves international sourcing and distribution of over-the-counter (OTC) medications, complemented by e-commerce supply chain management and logistical support in Hong Kong and mainland China. Not financial advice.
How frequently does HKPD data refresh on this page?
HKPD's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven HKPD's recent stock price performance?
Cellyan Biotechnology Co., Ltd (HKPD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on the over-the-counter (OTC) pharmaceutical sector in Hong Kong and mainland China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HKPD overvalued or undervalued right now?
Cellyan Biotechnology Co., Ltd (HKPD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HKPD before investing?
Before investing in Cellyan Biotechnology Co., Ltd (HKPD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (15 figures)
The 15 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.1095 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T08:44:35.833Z. | |
px.change | Change on the day | -2.06% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $1.20M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-05T08:44:34.805Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.0023 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q4 FY2026 | $6M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 259.8K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q4 FY2026 | -$1M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q4 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.scores | Distress and quality screens | Altman Z 3.53 · Piotroski F 4 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -15.4% · ROA -8.8% · current ratio 3.86 · earnings yield -28.6% · free-cash-flow yield -65.1% | — | UNRECORDED | Stored key metrics — Date unknown |
px.range52 | 52-week range | $0.096 – $1.72 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.employees | Employees | 27 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.ceo | Chief executive | Chenyu Liang | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 37 of 100 · Weak · pillars 47 / 36 / 73 / 0 / 9 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 37 (stored snapshot Oct 4, 2026) → 37 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.